Meihua International (NASDAQ: MHUA) closes $1,320,000 share sale

Rhea-AI Filing Summary

Meihua International Medical Technologies completed a Regulation S private placement of 120,000 class A ordinary shares at $11 per share, raising gross proceeds of $1,320,000. The company plans to use the net proceeds for working capital and general corporate purposes.

The December investors are non-U.S. persons and made customary investment, business condition, and legal representations under the securities purchase agreement. The filing also notes that in October 2025 Meihua privately placed 40,000,000 ordinary shares at $0.38 per share for gross proceeds of $15.2 million, and that it currently has 697,914 issued and outstanding class A ordinary shares.

Insights

Equity capital markets analyst

Meihua raises new equity capital through non-U.S. investor private placements under Regulation S.

Meihua International Medical Technologies entered a securities purchase agreement in December 2025 to sell 120,000 class A ordinary shares at $11 each, for gross proceeds of $1,320,000. The company states that net proceeds will be used for working capital and general corporate purposes, which can support ongoing operations without taking on debt.

The December purchasers are non-U.S. persons under Regulation S and provided customary representations about investment intent, absence of undisclosed material adverse effects, and lack of legal proceedings that would prevent closing. The company states that the December offering closed on December 15, 2025 and that it currently has 697,914 issued and outstanding class A ordinary shares, indicating that the new shares are now part of the equity base.

The filing also recalls an earlier October 2025 Regulation S private placement of 40,000,000 ordinary shares at $0.38 per share, for gross proceeds of $15.2 million, which had fully closed by October 17, 2025. Together, these transactions show the company using equity issuances to raise capital from non-U.S. investors, while the actual impact on existing holders depends on overall capital structure and future performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 12/16/2025 - 04:05 PM Learn about SEC filing dates

FAQ

What did Meihua (MHUA) announce in its December 2025 private placement?

Meihua International Medical Technologies agreed to sell up to 120,000 class A ordinary shares at $11 per share to non-U.S. investors under a securities purchase agreement.

How much capital did Meihua (MHUA) raise in the December 2025 offering?

The December 2025 private placement is for gross proceeds of $1,320,000 from the sale of 120,000 class A ordinary shares at $11 per share.

Who participated in Meihuas December 2025 private placement?

The December purchasers are described as non-U.S. persons under Regulation S of the Securities Act and are acquiring the shares for investment purposes.

How will Meihua (MHUA) use the proceeds from the December 2025 offering?

Meihua currently intends to use the net proceeds from the December offering for working capital and general corporate purposes.

How many class A ordinary shares does Meihua (MHUA) have outstanding after the December offering?

The company states that it currently has 697,914 issued and outstanding class A ordinary shares.

What earlier private placement did Meihua (MHUA) reference in this filing?

The filing notes an October 2025 private placement of 40,000,000 ordinary shares at $0.38 per share for gross proceeds of $15.2 million, which closed on October 17, 2025.

Under what exemption were Meihuas private placement shares issued?

Both the October and December offerings were conducted with non-U.S. persons in reliance on Regulation S under the Securities Act.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the Month of December 2025

Commission file number 001-41291

Meihua International Medical Technologies Co., Ltd.

(Translation of registrant’s name into English)

88 Tongda Road, Touqiao Town

Guangling District, Yangzhou, 225000

People’s Republic of China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒     Form 40-F  ☐

Closing of a Private Placement

As previously disclosed, Meihua International Medical Technologies Co., Ltd. (the “Company”) entered into a Securities Purchase Agreement with several “non-U.S. Persons” (the “October Purchasers”) as defined in Regulation S of the Securities Act of 1933, as amended (“the Securities Act”) on October 8, 2025 for a private placement (“October Offering”) of 40,000,000 ordinary shares of the Company, par value, $0.0005 per share, with the purchase price of $0.38 per share for the gross proceeds of $15.2 million. On October 17, the Company issued 40,000,000 ordinary shares to the October Purchasers and the October Offering was fully closed.

Entry into a Material Agreement and Closing of a Private Placement

On December 5, 2025, the Company entered into certain securities purchase agreement (the “SPA”) with certain “non-U.S. Persons” (the “December Purchasers”) as defined in Regulation S of the “Securities Act. Pursuant to the SPA, the Company agreed to sell up to an aggregate of 120,000 class A ordinary shares of the Company, par value $0.05 per share (“Shares”), with the purchase price of $11 per Share (the “December Offering”), for gross proceeds of $1,320,000. The Company currently intends to use the net proceeds from the December Offering for working capital and general corporate purposes.

The parties to the SPA have each made customary representations, warranties and covenants, including, among other things, (a) the December Purchasers are “non-U.S. Persons” as defined in Regulation S and are acquiring the Shares for the purpose of investment, (b) the absence of any undisclosed material adverse effect, and (c) the absence of legal proceedings that affect the completion of the transaction contemplated by the SPA.

On December 15, 2025, the December Offering was consummated, upon satisfaction of all of the closing conditions set forth in the SPA. The Shares were issued in reliance on the exemption from registration provided by Regulation S under the Securities Act. The Company currently has 697,914 issued and outstanding class A ordinary shares.

The form of the SPA is filed as Exhibit 99.1, and such document is incorporated herein by reference. The foregoing is only a brief description of the material terms of the SPA and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to such exhibit.

Exhibits

Exhibit No.		Description
99.1		Form of the Securities Purchase Agreement by and among the Company and the December Purchasers

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Meihua International Medical Technologies Co., Ltd.
By:	/s/ Leyi Lee
Name:	Leyi Lee
Title:	Chief Executive Officer
Date: December 16, 2025

2